Halozyme Posts $0.24 Q4 Loss Despite 51.6% Revenue Growth
Q4 adjusted loss was $0.24 per share while revenue rose 51.6% year-over-year to $451.8M, topping estimates by 0.7%. Full-year 2025 revenue reached $1.397B, driven by $868M in royalty income, and 2026 guidance calls for $1.71–$1.81B revenue and $7.75–$8.25 EPS.
1. Q4 Financial Results
Halozyme reported an adjusted loss of $0.24 per share in Q4, a sharp reversal from $1.26 profit a year earlier, missing consensus estimates by over $2.00. Revenue climbed 51.6% year-over-year to $451.8 million, a 0.7% beat driven by strong ENHANZE royalties and service revenues.
2. 2025 Full-Year Performance
Full-year total revenue hit a record $1.397 billion, up 38% year-over-year, as royalty revenue from ENHANZE-enabled products surged 52% to $868 million. Growth was propelled by expanded patient uptake of subcutaneous formulations for multiple blockbuster drugs.
3. 2026 Financial Guidance
The company issued guidance for 2026 revenue of $1.71–$1.81 billion (22–30% growth) and non-GAAP EPS of $7.75–$8.25 (87–99% growth), with adjusted EBITDA set between $1.125–$1.205 billion. Management highlighted sustained royalty momentum and cost discipline as key drivers.
4. Strategic Portfolio Expansion
In late 2025, Halozyme acquired Surf Bio’s hyperconcentration technology and Elektrofi’s Hypercon platform, broadening its drug delivery portfolio. These additions aim to secure new collaboration agreements and extend royalty opportunities into the mid-2040s.